# Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

> **NCT00064103** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (actual)

## Conditions studied

- Lip and Oral Cavity Cancer
- Oropharyngeal Cancer
- Stage 0 Lip and Oral Cavity Cancer
- Stage 0 Oropharyngeal Cancer
- Tongue Cancer

## Interventions

- **BIOLOGICAL:** Ad5CMV-p53 gene
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00064103
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064103, "Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00064103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*